進行性固形腫瘍患者を対象とした、免疫調節受容体を標的とするASP1948の単剤療法およびPD-1阻害剤（ニボルマブまたはペムブロリズマブ）との併用療法に関する研究

基本情報

NCT ID

NCT03565445

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

190

治験依頼者名

Astellas Pharma Inc

概要

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab.

対象疾患

介入

依頼者（Sponsor）